Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Understanding leukemic stem cell (LSC) is important for acute myeloid leukemia (AML) treatment. However, association of LSC with patient prognosis and genetic information in AML patients is unclear. Methods: Here we investigated the associations between genetic information and the various LSC phenotypes, namely multipotent progenitor (MPP)-like, lymphoid primed multipotent progenitor (LMPP)-like and granulocyte-macrophage progenitors (GMP)-like LSC in 52 AML patients. Results: In secondary AML patients, MPP-like LSC was significantly higher than de novo AML (p = 0.0037). The proportion of MPP-like LSC was especially high in post-myeloproliferative neoplasm AML (p = 0.0485). There was no correlation between age and LSC phenotype. Mutations of KRAS and NRAS were observed in MPP-like LSC dominant patients, TP53 and ASXL1 mutations in LMPP-like LSC dominant patients, and CEBPA, DNMT3A and IDH1 mutations in GMP-like LSC dominant patients. Furthermore, KRAS mutation was significantly associated with MPP-like LSC expression (p = 0.0540), and TP53 mutation with LMPP-like LSC expression (p = 0.0276). When the patients were separated according to the combined risk including next generation sequencing data, the poorer the prognosis, the higher the LMPP-like LSC expression (p = 0.0052). This suggests that the dominant phenotype of LSC is one of the important factors in predicting the prognosis and treatment of AML. Conclusions: LSC phenotype in AML is closely associated with the recurrent mutations which has prognostic implication. Further research to confirm the meaning of LSC phenotype in the context of genetic aberration is warranted.
Abstract
Background/Aims: Understanding leukemic stem cell (LSC) is important for acute myeloid leukemia (AML) treatment. However, association of LSC with patient prognosis and genetic information in AML patients is unclear. Methods: Here we investigated the associations between genetic information and the various LSC phenotypes, namely multipotent progenitor (MPP)-like, lymphoid primed multipotent progenitor (LMPP)-like and granulocyte-macrophage progenitors (GMP)-like LSC in 52 AML patients. Results: In secondary AML patients, MPP-like LSC was significantly higher than de novo AML (p = 0.0037). The proportion of MPP-like LSC was especially high in post-myeloproliferative neoplasm AML (p = 0.0485). There was no correlation between age and LSC phenotype. Mutations of KRAS and NRAS were observed in MPP-like LSC dominant patients, TP53 and ASXL1 mutations in LMPP-like LSC dominant patients, and CEBPA, DNMT3A and IDH1 mutations in GMP-like LSC dominant patients. Furthermore, KRAS mutation was significantly associated with MPP-like LSC expression (p = 0.0540), and TP53 mutation with LMPP-like LSC expression (p = 0.0276). When the patients were separated according to the combined risk including next generation sequencing data, the poorer the prognosis, the higher the LMPP-like LSC expression (p = 0.0052). This suggests that the dominant phenotype of LSC is one of the important factors in predicting the prognosis and treatment of AML. Conclusions: LSC phenotype in AML is closely associated with the recurrent mutations which has prognostic implication. Further research to confirm the meaning of LSC phenotype in the context of genetic aberration is warranted.
참고문헌 (39)
- Cancer Genome Atlas Research Network, "Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia", N Engl J Med, 368, pp.2059~2074 (2013)
- Papaemmanuil E, "Genomic classification and prognosis in acute myeloid leukemia", N Engl J Med, 374, pp.2209~2221 (2016)
- Estey EH, "Acute myeloid leukemia : 2019 update on risk-stratification and management", Am J Hematol, 93, pp.1267~1291 (2018)
- Thomas D, "Biology and relevance of human acute myeloid leukemia stem cells", Blood, 129, pp.1577~1585 (2017)
- Pollyea DA, "Targeting acute myeloid leukemia stem cells : a review and principles for the development of clinical trials", Haematologica, 99, pp.1277~1284 (2014)
- Pollyea DA, "Therapeutic targeting of acute myeloid leukemia stem cells", Blood, 129, pp.1627~1635 (2017)
- Riether C, "Regulation of hematopoietic and leukemic stem cells by the immune system", Cell Death Differ, 22, pp.187~198 (2015)
- Taussig DC, "Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells", Blood, 112, pp.568~575 (2008)
- Plesa A, "High frequency of CD34+CD38-", low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia, 2017, pp.9, 227~234
- Kreso A, "Evolution of the cancer stem cell model", Cell Stem Cell, 14, pp.275~291 (2014)
- Vardiman JW, "The 2008 revision of the World Health Organization(WHO)classification of myeloid neoplasms and acute leukemia : rationale and important changes", Blood, 114, pp.937~951 (2009)
- Brothman AR, "Nomenclature evolution : changes in the ISCN from the 2005 to the 2009edition", Cytogenet Genome Res, 127, pp.1~4 (2009)
- Slovak ML, "Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia : a Southwest Oncology Group", Eastern Cooperative Oncology Group Study, 2000, pp.96, 4075~4083
- Dohner H, "Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel", Blood, 129, pp.424~447 (2017)
- Goardon N, "Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia", Cancer Cell, 19, pp.138~152 (2011)
- Vergez F, "High levels of CD34+CD38low", -CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia : a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang(GOELAMS)study, 2011, pp.96, 1792~1798
- Li H, "Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly", Bioinformatics, 28, pp.1838~1844 (2012)
- Van der Auwera GA, "From FastQ data to high confidence variant calls : the Genome Analysis Toolkit best practices pipeline", Curr Protoc Bioinformatics, 43, pp.11~ (2013)[DOI]
- Wei Z, "SNVer : a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data", Nucleic Acids Res, 39, pp.e132~ (2011)
- Wilm A, "LoFreq : a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets", Nucleic Acids Res, 40, pp.11189~11201 (2012)
- Chen X, "Manta : rapid detection of structural variants and indels for germline and cancer sequencing applications", Bioinformatics, 32, pp.1220~1222 (2016)
- Rausch T, "DELLY : structural variant discovery by integrated paired-end and split-read analysis", Bioinformatics, 28, pp.i333~i339 (2012)
- Oesper L, "Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data", Bioinformatics, 30, pp.3532~3540 (2014)
- Talevich E, "CNVkit : genome-wide copy number detection and visualization from targeted DNA sequencing", PLoS Comput Biol, 12, pp.e1004873~ (2016)
- Cingolani P, "A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3", Fly(Austin), 6, pp.80~92 (2012)
- O’Leary NA, "Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation", Nucleic Acids Res, 44(D1), pp.D733~D745 (2016)
- Tate JG, "COSMIC : the Catalogue Of Somatic Mutations In Cancer", Nucleic Acids Res, 47(D1), pp.D941~D947 (2019)
- Sherry ST, "dbSNP : the NCBI database of genetic variation", Nucleic Acids Res, 29, pp.308~311 (2001)
- Landrum MJ, "ClinVar : public archive of relationships among sequence variation and human phenotype", Nucleic Acids Res, 42(Database issue), pp.D980~D985 (2014)
- Lek M, "Analysis of protein-coding genetic variation in 60, 706 humans", Nature, 536, pp.285~291 (2016)
- Dean M, "Tumour stem cells and drug resistance", Nat Rev Cancer, 5, pp.275~284 (2005)
- Raaijmakers MH, "ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia", Leukemia, 21, pp.2094~2102 (2007)
- Wang X, "Understanding of leukemic stem cells and their clinical implications", Mol Cancer, 16, pp.2~ (2017)
- Craddock C, "Azacitidine fails to eradicate leukemic stem", progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia, 2013, pp.27, 1028~1036
- Corces-Zimmerman MR, "Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission", Proc Natl Acad Sci U S A, 111, pp.2548~2553 (2014)
- Corces-Zimmerman MR, "Pre-leukemic evolution of hematopoietic stem cells : the importance of early mutations in leukemogenesis", Leukemia, 28, pp.2276~2282 (2014)
- Zhou JD, "KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia", Oncotarget, 8, pp.66087~66097 (2017)
- DiNardo CD, "Mutations in AML : prognostic and therapeutic implications", Hematology Am Soc Hematol Educ Program, 2016, pp.348~355 (2016)
- Liu X, "RAS mutations in acute myeloid leukaemia patients : a review and meta-analysis", Clin Chim Acta, 489, pp.254~260 (2019)